Chimerix (NASDAQ:CMRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Chimerix (NASDAQ:CMRX - Get Free Report) in a research note issued to investors on Saturday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.

A number of other research firms have also recently weighed in on CMRX. HC Wainwright reissued a "neutral" rating and issued a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reissued a "hold" rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Wedbush reissued a "neutral" rating and issued a $8.55 price objective (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

CMRX traded up $0.01 during trading on Friday, hitting $8.48. 1,494,109 shares of the stock were exchanged, compared to its average volume of 2,077,683. The firm has a 50 day simple moving average of $4.94 and a 200 day simple moving average of $2.64. The firm has a market cap of $762.66 million, a price-to-earnings ratio of -9.02 and a beta of 0.32. Chimerix has a 1 year low of $0.75 and a 1 year high of $8.48.

Remove Ads

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Chimerix

Institutional investors have recently modified their holdings of the stock. Deerfield Management Company L.P. Series C purchased a new position in shares of Chimerix in the 4th quarter valued at about $13,124,000. Rosalind Advisors Inc. purchased a new position in shares of Chimerix in the 4th quarter valued at about $10,614,000. Boxer Capital Management LLC purchased a new position in shares of Chimerix in the 4th quarter valued at about $7,169,000. Marshall Wace LLP increased its stake in shares of Chimerix by 1,318.5% in the 4th quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company's stock valued at $7,705,000 after purchasing an additional 2,057,864 shares in the last quarter. Finally, Peapod Lane Capital LLC purchased a new stake in Chimerix during the 4th quarter worth approximately $2,626,000. Hedge funds and other institutional investors own 45.42% of the company's stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.